Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Texas Instruments Incorporated — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Texas Instruments Incorporated trades at $279.4 (market cap $262.88B). The key difference: Texas Instruments Incorporated is far larger — about 53.9× Travere Therapeutics Inc. Common Stock's market cap, and Texas Instruments Incorporated pays a 2.11% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Texas Instruments Incorporated for 77 Days on average.
| TVTX | TXN | |
|---|---|---|
Market Cap | $4.88B | $262.88B |
Volume | 1,668,577 | 5,600,379 |
Sector | Health | Technology |
52-Week High | $67.52 | $332.35 |
52-Week Low | $26.79 | $153.33 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $5.01B | $269.93B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Texas Instruments (TXN) trades at $281.74, down 0.7% on the day, with a neutral technical signal. The stock shows strong profitability with a 31.11% net income margin and 34.97% ROE, though valuation ratios like a P/E of 43.75 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and data center sales growth is a key driver, with news highlighting a 55% year-to-date gain as of September 2026.
The outlook is positive with a consensus price target of $325, implying 15% upside, supported by AI and industrial demand. Risks include high debt-to-asset ratio of 40.61% and semiconductor cycle volatility. Analyst sentiment is mixed but leans bullish with 48% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
